País: Irlanda
Idioma: inglés
Fuente: HPRA (Health Products Regulatory Authority)
Derquantel; Abamectin
Zoetis Belgium S.A.
QP54AA52
Derquantel; Abamectin
10,1 milligram(s)/millilitre
Oral solution
POM: Prescription Only Medicine as defined in relevant national legislation
Sheep
abamectin, combinations
Endectoparasiticides
Authorised
2013-12-09
1. NAME OF THE VETERINARY MEDICINAL PRODUCT Startect Dual Active oral solution for sheep 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains: ACTIVE SUBSTANCES: Derquantel 10 mg Abamectin 1.0 mg EXCIPIENTS: QUALITATIVE COMPOSITION OF EXCIPIENTS AND OTHER CONSTITUENTS QUANTITATIVE COMPOSITION IF THAT INFORMATION IS ESSENTIAL FOR PROPER ADMINISTRATION OF THE VETERINARY MEDICINAL PRODUCT Butylhydroxytoluene 0.5 mg Glycerol formal Triacetin Propylene glycol dicaprylocaprate Oral solution. A clear to hazy, colourless to yellow-brown solution. 3. CLINICAL INFORMATION 3.1 TARGET SPECIES Sheep. 3.2 INDICATIONS FOR USE FOR EACH TARGET SPECIES Startect Dual Active is a broad spectrum anthelmintic for the treatment and control of mixed gastro- intestinal nematode infections and associated diseases of sheep. The spectrum of activity is as follows: ADULT AND IMMATURE GASTRO-INTESTINAL NEMATODES: _Haemonchus contortus _ (including inhibited larval stages) _ _ _Teladorsagia (Ostertagia) circumcincta _ (including inhibited larval stages) _ _ _Teladorsagia (Ostertagia) trifurcata _ _Trichostrongylus axei _ _Trichostrongylus colubriformis _ _Trichostrongylus vitrinus _ _Cooperia curticei _ _Cooperia oncophora _ _Nematodirus spathiger _ _Nematodirus filicollis _ _Nematodirus battus _ _Strongyloides papillosus _ _Oesophagostomum venulosum _ (adult) _ _ _Trichuris ovis _ _Chabertia ovina_ LUNGWORMS: _Dictyocaulus filaria _ (adult) _ _ This product is effective against strains of parasites resistant to benzimidazoles, levamisole, macrocyclic lactones, and combinations of these. 3.3 CONTRAINDICATIONS Do not use in dogs as severe adverse reactions may occur. Do not use in horses as severe adverse reactions, including fatalities, will occur. Do not exceed the recommended dose rate. Do not use in cases of hypersensitivity to the active substances or to any of the excipients. 3.4 SPECIAL WARNINGS Care should be taken to avoid the following practices because they increase the risk of development of resistance and could ultimately r Leer el documento completo